SuperworthNewAmsterdam Pharma price to sales ratio NAMS
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- n/m
- a sliver of sales
- Last meaningful
- 144×
- Jul 2026
- Peer median
- 2.0×
NewAmsterdam Pharma's price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.
It was last meaningful in Jul 2026, at 144×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 144× | 100× | 184× |
| 2025 | 113× | 36.4× | 133× |
| 2024 | 71.1× | 50.5× | 71.1× |
Against its peers
Companies in Drug Manufacturers - General nearest NewAmsterdam Pharma's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| NAMSNewAmsterdam Pharma | n/m |
| PBHPrestige Consumer Healthcare | 2.0× |
| HRMYHarmony Biosciences | 2.2× |
| NRIXNurix Therapeutics | 3.9× |
| ANIPANI Pharmaceuticals | 1.7× |
| PAHCPhibro Animal Health | 1.0× |
| OGNOrganon | 0.6× |
| ANABAnaptysbio | n/m |
| LQDALiquidia | 8.5× |
| PCRXPacira BioSciences | 1.9× |
| ARQTArcutis Biotherapeutics | 8.5× |
| Peer median | 2.0× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on NewAmsterdam Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.